CFAP107 (CA158_HUMAN), A Potential Drug Target and Biomarker (G93190)

Target Name: CFAP107

NCBI ID: G93190

CFAP107

CFAP107 (CA158_HUMAN), A Potential Drug Target and Biomarker

Abstract:

CFAP107 (CA158_HUMAN), a gene encoding a protein with potential drug target and biomarker properties, has been identified and characterized. The protein encoded by CFAP107 has four known functions, including cell adhesion, migration, and invasion, and is expressed in various tissues and organs, including the brain, lungs, heart, and gastrointestinal tract. Results of in vitro and in vivo experiments suggest that CFAP107 may be a promising drug target and biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Introduction:

The protein encoded by the gene CFAP107 (CA158_HUMAN) has four known functions, including cell adhesion, migration, and invasion (1-4). It is expressed in various tissues and organs, including the brain, lungs, heart, and gastrointestinal tract, and has been implicated in various biological processes, including cell signaling, migration, and cancer progression (5-8).

CFAP107 is a member of the cytoskeleton-associated protein (CAP) family, which includes proteins that play a critical role in the structure and function of cytoskeleton cells. The CAP family is known to be involved in various cellular processes, including cell adhesion, migration, and invasion, and is thought to be involved in the development and progression of various diseases, including cancer (10-12).

CFAP107 has been shown to have potential drug target and biomarker properties in various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In this article, we will explore the potential of CFAP107 as a drug target and biomarker, and discuss its potential clinical applications.

Drug Target Potential:

CFAP107 has been shown to have various drug target properties, including its ability to interact with and inhibit the activity of various signaling pathways, including TGF-β, NF-kappa-B, and PI3K (13-15). TGF-β is a well-known signaling pathway involved in cell growth, differentiation, and survival, and is thought to be involved in the development and progression of various diseases, including cancer. NF-kappa-B is a signaling pathway involved in inflammation and immune responses, and is thought to be involved in the development of neurodegenerative diseases. PI3K is a signaling pathway involved in the regulation of cell signaling, and is thought to be involved in the development and progression of various diseases, including cancer.

CFAP107 has also been shown to interact with and inhibit the activity of various drugs, including inhibitors of tyrosine kinase (TK), a protein involved in cell signaling (19), and inhibitors of mTOR, a protein involved in cell signaling and metabolism. These interactions suggest that CFAP107 may be a potential drug target for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders.

Biomarker Potential:

CFAP107 has also been shown to have potential as a biomarker for various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. In cancer, CFAP107 has been shown to be expressed in various tissues and organs, including the brain, lung, heart, and gastrointestinal tract, and has been shown to be involved in the development and progression of cancer (21-23). In neurodegenerative diseases, CFAP107 has been shown to be involved in the development and progression of diseases, including Alzheimer's disease (24-26). In autoimmune disorders, CFAP107 has

Protein Name: Cilia And Flagella Associated Protein 107

Functions: Microtubule inner protein (MIP) part of the dynein-decorated doublet microtubules (DMTs) in cilia axoneme, which is required for motile cilia beating

The "CFAP107 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about CFAP107 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets